Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Citigroup Maintains Buy on DocuSign, Raises Price Target to $288

Citigroup analyst Tyler Radke maintains DocuSign (NASDAQ:DOCU) with a Buy and raises the price target from $282 to $288.

byBenzinga Newsdesk

June 4, 2021

1 minute read

Citigroup analyst Tyler Radke maintains DocuSign (NASDAQ:DOCU) with a Buy and raises the price target from $282 to $288.

B of A Securities Initiates Coverage On Thoughtworks Holding with Neutral Rating, Announces Price Target of $28

By Benzinga Newsdesk

Today, 3:07 AM

B of A Securities analyst Jason Kupferberg initiates coverage on Thoughtworks Holding (NASDAQ:TWKS) with a Neutral rating and announces Price Target of $28.

TWKS

FDA
News

FDA Approves First Generic Of Restasis. BZ NOTE: AbbVie Manufactures Restasis

By Benzinga Newsdesk

Today, 3:07 AM

FDA Approves First Generic of Restasis SILVER SPRING, Md., Feb. 2, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration has approved the first generic of Restasis (cyclosporine ophthalmicFDA Approves First Generic of Restasis

ABBV

News

SRAX Launches Microcaps.com

By Bill Haddad

Today, 3:07 AM

SRAX, Inc. (NASDAQ:SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has launched Microcaps.com, an editorial content and curated news

SRAX